Homology Medicines Valuation
| FIXXDelisted Stock | USD 1.09 0.06 5.83% |
Today, the firm appears to be overvalued. Homology Medicines retains a regular Real Value of $0.88 per share. The prevalent price of the firm is $1.09. Our model calculates the value of Homology Medicines from evaluating the firm fundamentals such as Shares Outstanding of 3.23 M, return on equity of -0.9, and Return On Asset of -0.36 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Homology Medicines' price fluctuation is very steady at this time. Calculation of the real value of Homology Medicines is based on 3 months time horizon. Increasing Homology Medicines' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Homology Medicines is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Homology Stock. However, Homology Medicines' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.09 | Real 0.88 | Hype 1.09 |
The intrinsic value of Homology Medicines' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Homology Medicines' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Homology Medicines helps investors to forecast how Homology stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Homology Medicines more accurately as focusing exclusively on Homology Medicines' fundamentals will not take into account other important factors: Homology Medicines Total Value Analysis
Homology Medicines is currently anticipated to have valuation of (27 M) with market capitalization of 3.02 M, debt of 1.32 M, and cash on hands of 201.07 M. The negative valuation of Homology Medicines may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Homology Medicines fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(27 M) | 3.02 M | 1.32 M | 201.07 M |
Homology Medicines Investor Information
About 47.0% of the company shares are owned by institutional investors. The company has price-to-book (P/B) ratio of 0.04. Some equities with similar Price to Book (P/B) outperform the market in the long run. Homology Medicines recorded a loss per share of 35.1. The entity had not issued any dividends in recent years. The firm had 1:18 split on the 25th of March 2024. Based on the key indicators related to Homology Medicines' liquidity, profitability, solvency, and operating efficiency, Homology Medicines is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Homology Medicines Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Homology Medicines has an asset utilization ratio of 0.38 percent. This suggests that the Company is making $0.003776 for each dollar of assets. An increasing asset utilization means that Homology Medicines is more efficient with each dollar of assets it utilizes for everyday operations.Homology Medicines Ownership Allocation
30% of Homology Medicines outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.Homology Medicines Profitability Analysis
The company reported the previous year's revenue of 1.16 M. Net Loss for the year was (112.96 M) with loss before overhead, payroll, taxes, and interest of (95.14 M).About Homology Medicines Valuation
Our relative valuation model uses a comparative analysis of Homology Medicines. We calculate exposure to Homology Medicines's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Homology Medicines's related companies.Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts. Homology Medicines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 224 people.
Homology Medicines Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 57.8 M | |
| Forward Price Earnings | 22.2717 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Other Consideration for investing in Homology Stock
If you are still planning to invest in Homology Medicines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Homology Medicines' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |